SequelSEC

OptimizeRx Corp OPRX

Services-Business Services, NEC · CIK 0001448431 · Fiscal year ends 1231

Revenue
$98.65M
Fiscal year ended 2026-06-30
Operating income
$10.93M
Fiscal year ended 2026-06-30
Free cash flow
$18.36M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$240.86MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$12.84Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income46.9×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue2.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

Valuation over time

46.9× earnings today, against a median of 361.1× across 3 years on record. Below its own history.

Float measuredPublic floatFloat / net income
2025-06-30$240.86M46.9×
2021-06-30$1.03B2724.5×
2018-06-30$81.73M361.1×

Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.

How this compares in its industry

Percentile among the Services-Business Services, NEC filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue0.0%0th
CapEx / revenue0.1%10th
Long-term debt / equity0.17x10th
Current ratio3.04x86th
Revenue YoY growth18.8%76th
FCF margin17.0%73th
Gross margin67.3%70th
SBC / revenue6.4%69th
Operating margin10.7%68th
Effective tax rate26.2%63th
Net margin4.7%56th

OptimizeRx Corp (OPRX) reported revenue of $98.65M and net income of $4.60M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from OptimizeRx Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Business Services, NEC.

Income

OptimizeRx Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$98.65M
Cost of revenue$26.42M
Gross profit$72.24M
Operating income$10.93M
Net income$4.60M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income$6.78M
Income tax expense$2.18M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

OptimizeRx Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$24.10M
Total assets$164.32M
Current assets$54.15M
Total liabilities$33.24M
Current liabilities$9.71M
Total equity incl. NCI$131.08M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$24.80M
Goodwill$70.87M
Long-term debt$17.76M
Accounts payableUnavailable

Cash flow

OptimizeRx Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$18.43M
Capital expenditures$77.00K
Investing cash flow$140.00K
Financing cash flow-$11.07M
Net change in cash$7.51M
Stock-based compensation$7.95M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$4.29M

Derived

OptimizeRx Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$18.36M
Gross margin73.2%
Operating margin11.1%
FCF margin18.6%
SBC / revenue8.1%
Current ratio5.58x
Revenue YoY growth-5.8%
Net margin4.7%
R&D / revenueUnavailable
CapEx / revenue0.1%
Long-term debt / equity0.14x
Effective tax rate32.1%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OPRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.